🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

647 results for “Les” Clear

  1. "myk-461 capsules, placebo is a solid oral dosage form in size 2 gelatin capsules each containing 120 mg of an excipient blend. it is intended as a placebo to match myk-461 capsules of all active strengths", Mavacamten, Mavacamten, Mavacamten, Mavacamten, Mavacamten

    Bristol-Myers Squibb Australia Pty Ltd

    Symptomatic Obstructive Hypertrophic Cardiomyopathy

    phase 3 small molecule active

    1 trial

  2. -, COLESTYRAMINE , AUBAGIO 14 mg film-coated tablets, -, Matched Placebo to Test, Tolebrutinib, Matched Placebo for Comparator Teriflunomide

    Sanofi-aventis Healthcare Pty Ltd

    Nervous system diseases

    phase 3 small molecule active

    1 trial

  3. 2 cycles induction chemotherapy

    The First People's Hospital of Lianyungang

    Locally Advanced Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  4. 64Cu(II)Cl2 solution for injection, Fluorocolina (18F) Curium Italy 225 MBq/mL soluzione iniettabile

    A.C.O.M. - Advanced Center Oncology

    Prostate cancer at risk of developing metastatic lesions

    phase 3 small molecule active

    1 trial

  5. A Two-Part, Seamless, Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Patients With Spinal Muscular Atrophy

    Hoffmann-La Roche

    Spinal Muscular Atrophy (SMA)

    phase 3 other active

    1 trial

  6. A multi-centre, single arm, open-label extension study to evaluate the long-term safety of GSK3511294 (Depemokimab) in adult and adolescent participants with severe asthma with an eosinophilic phenotype from studies 206713 or 213744

    GlaxoSmithKline

    Severe asthma with an eosinophilic phenotype

    phase 3 other active

    1 trial

  7. A phase 3, prospective, open-label, multisite, extension of phase 3 studies to assess the long-term safety and tolerability of soticlestat as adjunctive therapy in subjects with Dravet Syndrome or Lennox-Gastaut Syndrome (ENDYMION 2)

    Takeda

    Dravet and Lennox-Gastaut Syndromes

    phase 3 other active

    1 trial

  8. ASP8825

    Astellas Pharma Inc

    Restless Legs Syndrome

    phase 3 small molecule completed

    1 trial

  9. AUBAGIO 14 mg film-coated tablets, COLESTYRAMINE , -, Matched Placebo to Test, Matched Placebo for Comparator Teriflunomide, Tolebrutinib, -

    Sanofi-aventis Healthcare Pty Ltd

    Nervous system diseases

    phase 3 small molecule active

    1 trial

  10. AUBAGIO 14 mg film-coated tablets, Frexalimab, AUBAGIO 14 mg film-coated tablets, AUBAGIO 14 mg film-coated tablets, COLESTYRAMINE , AUBAGIO 14 mg film-coated tablets, Matched placebo for comparator teriflunomide, AUBAGIO 14 mg film-coated tablets, Matched placebo for test product frexalimab

    Sanofi-aventis Healthcare Pty Ltd

    multiple sclerosis

    phase 3 small molecule active

    1 trial

  11. AZD0120, Bortezomib Hikma 3,5 mg Pulver zur Herstellung einer Injektionslösung, DARZALEX 1800 mg solution for injection, Dexamethason 1,5 mg JENAPHARM®, Kyprolis 10 mg powder for solution for infusion, Dexamethason 0,5 mg JENAPHARM®, Pomalidomide Zentiva 3 mg hard capsules, Pomalidomide Zentiva 2 mg hard capsules, Dexamethason 4 mg JENAPHARM, Kyprolis 30 mg powder for solution for infusion, Pomalidomide Zentiva 1 mg hard capsules, Pomalidomide Zentiva 4 mg hard capsules, Kyprolis 60 mg powder for solution f

    AstraZeneca AB

    Relapsed or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  12. AZD0780

    AstraZeneca

    Heterozygous Familial Hypercholesterolaemia

    phase 3 small molecule active

    1 trial

  13. AZD0780 Placebo, AZD0780

    AstraZeneca AB

    Heterozygous familial hypercholesterolaemia

    phase 3 small molecule active

    1 trial

  14. AchilleS tendinoPathy treated with cortIcosteRoid injEctions.

    Disc Medicine

    Achilles tendinopathy

    phase 3 other active

    1 trial

  15. Afinitor 2.5 mg tablets, Afinitor 10 mg tablets

    The George Institute

    Children, adolescents and adults with newly diagnosed diffuse intrinsic pontine glioma and other diffuse midline gliomas H3K28M mutant or EZHIP positive

    phase 3 small molecule active

    1 trial

  16. Alecensa 150 mg hard capsules, IMFINZI 50 mg/mL concentrate for solution for infusion.

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  17. Alecensa 150 mg hard capsules, VINORELBINE, Gemcitabin-GRY 1000 mg Pulver zur Herstellung einer Infusionslösung, Carboplatin-GRY® 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin ACTAVIS 10 mg/ml concentrat pentru soluţie perfuzabilă, ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Alecensa 150 mg hard capsules

    Hoffmann-La Roche

    Completely resected, Stage Ib (tumors ≥ 4 cm) to Stage IIIa, Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  18. Alirocumab

    Regeneron UK Limited

    Hypercholesterolaemia

    phase 3 small molecule completed

    2 trials

  19. Alirocumab

    Sanofi Pasteur

    Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  20. Alirocumab

    Regeneron UK Limited

    Homozygous Familial Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  21. Alirocumab

    Regeneron UK Limited

    Hypercholesterolemia

    phase 3 small molecule active

    18 trials

  22. Alirocumab SAR236553

    Regeneron UK Limited

    Hypercholesterolaemia

    phase 3 small molecule completed

    1 trial

  23. Apremilast, Apremilast, Apremilast

    Amgen

    Behçet’s disease is a chronic, relapsing, multisystem inflammatory disorder of unknown etiology characterized by 4 major symptoms (oral aphthous ulcers, genital ulcers, skin lesions, and ocular lesions) and occasionally by 5 minor symptoms (arthritis, gastrointestinal ulcers, epididymitis, vascular lesions, and central nervous system [CNS] symptoms) (Cho, 2012). Juvenile idiopathic arthritis is a heterogeneous group of chronic inflammatory disorders that initially presents in children by the age of 16 years. It refers to arthritis of at least 6 weeks duration of unknown etiology that begins in children less than 16 years old. Juvenile idiopathic arthritis has an annual incidence of 2 to 20 cases per 100 000 population and a prevalence of 16 to 150 cases per 100 000 population. It is an autoimmune disorder marked by abnormalities of immune responses (Adelowo, 2010).

    phase 3 small molecule active

    1 trial

  24. Atomoxetine Aurobindo 40 mg hard capsules, Microcrystalline cellulose gelatin capsule

    Disc Medicine

    Parkinson's disease

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources